KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

January 31, 2029

Conditions

Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveMultiple SclerosisMS

Interventions

BIOLOGICAL

KYV-101

Anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

CYC/FLU

DRUG

Anti-CD20 mAB

Trial Locations (1)

Stanford University Medical Center, Palo Alto